NCT05346783

Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients

A Phase 1/2. Multicenter, Randomized, Double-blinded, Placebo and Active-controlled, Parallel Study for Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 98 (estimated)
• Sponsor: Taejoon Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective randomized study compared with active control and placebo arms.

Conditions

• Dry Eye Syndromes

Interventions

Type	Name	Description
DRUG	TJO-083	Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
OTHER	Placebo (vehicle)	1 drop 6 times a day
DRUG	Diquafosol ophthalmic sodium solution 3%	Diquafosol ophthalmic sodium solution, 1 drop 6 times a day

Timeline

• Start date: 2021-10-14
• Primary completion: 2022-12-01
• Completion: 2023-06-01
• First posted: 2022-04-26
• Last updated: 2022-04-26

Locations

1 site across 1 country: South Korea